MHRA opens consultation for reclassification of drugs

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued public consultations for the reclassification of four pharmacy drugs: Freederm Gel (4% nicotinamide), Bazuka gel (salicylic acid 12% w/w and lactic acid 4.0% w/w), Hedrin lotion (dimeticone 4%) and Nicorette nasal spray (nicotine 10mg/ml).

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued public consultations for the reclassification of four pharmacy drugs: Freederm Gel (4% nicotinamide), Bazuka gel (salicylic acid 12% w/w and lactic acid 4.0% w/w), Hedrin lotion (dimeticone 4%) and Nicorette nasal spray (nicotine 10mg/ml).

The public consultations call for views on each product to change their status from Pharmacy (P) to General Sales List...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

More from Therapeutic Category

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?